Abstract
Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer’s disease (AD) patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and chitinase-3-like protein 1 (YKL-40) levels with brain amyloid-β (Aβ) and tau pathologies. We assessed 121 individuals across the aging and AD clinical spectrum with positron emission tomography (PET) brain imaging for Aβ ([18F]AZD4694) and tau ([18F]MK6240), as well as CSF GFAP and YKL-40 measures. We observed that higher CSF GFAP levels were associated with elevated Aβ-PET but not tau-PET load. By contrast, higher CSF YKL-40 levels were associated with elevated tau-PET but not Aβ-PET burden. Structural equation modeling revealed that CSF GFAP and YKL-40 mediate the effects of Aβ and tau, respectively, on hippocampal atrophy, ultimately leading to cognitive impairment. Our results suggest the existence of distinct astrocyte biomarker signatures in response to brain Aβ and tau accumulation, which may contribute to our understanding of the complex link between reactive astrogliosis heterogeneity and AD progression.
Competing Interest Statement
S.G. has served as a scientific advisor to Cerveau Therapeutics. K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. All other authors declare no competing interests.
Funding Statement
This research is supported by the Weston Brain Institute, Canadian Institutes of Health Research (#MOP-11-51-31; RFN 152985, 159815, 162303; P.R-N.), Canadian Consortium of Neurodegeneration and Aging (MOP-11-51-31 - team 1; P.R-N.), the Alzheimer's Association (#NIRG-12-92090, #NIRP-12-259245; P.R-N.), Brain Canada Foundation (CFI Project 34874; 33397; P.R-N.), the Fonds de Recherche du Québec - Santé (Chercheur Boursier, #2020-VICO-279314; P.R-N.). T.A.P., P.R-N., and S.G. are members of the CIHR-CCNA Canadian Consortium of Neurodegeneration in Aging. T.A.P. is supported by the NIH (#R01AG075336 and #R01AG073267) and the Alzheimer's Association (#AACSF-20-648075). J.P.F-S. receives financial support from CAPES [88887.627297/2021-00]. B.B. receives financial support from CAPES (#88887.336490/2019-00). C.T. receives funding from Faculty of Medicine McGill and IPN McGill. D.T.L. is supported by a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (#29486). W.S.B. is supported by CAPES (#88887.372371/2019-00 and #88887.596742/2020-00). A.L.B. is supported by the Swedish Alzheimer Foundation, Stiftelsen för Gamla Tjänarinnor, and Stohne Stiftelsen. M.A.D.B. receives financial support from CNPq (#150293/2019-4). J.T. is supported by the Canadian Institutes of Health Research & McGill Healthy Brains Healthy Lives initiative. K.B. is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (#JPND2019-466-236), the NIH (#1R01AG068398-01), and the Alzheimer’s Association 2021 Zenith Award (#ZEN-21-848495). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden (#FO2019-0228), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. D.O.S. is supported by CAPES (#88887.185806/2018-00, #88887.507218/2020-00, and #88887.507161/ 2020-00), CNPQ/INCT (#465671/2014-4), CNPQ/ZIKA (#440763/ 2016-9), CNPQ/FAPERGS/PRONEX (#16/2551- 0000475-7), and FAPERGS (#19/2551-0000700-0). T.K.K. is funded by the Swedish Research Council's career establishment fellowship (#2021-03244), the Alzheimer's Association Research Fellowship (#850325), the BrightFocus Foundation (#A2020812F), the International Society for Neurochemistry's Career Development Grant, the Swedish Alzheimer Foundation (Alzheimerfonden; #AF-930627), the Swedish Brain Foundation (Hjärnfonden; #FO2020-0240), the Swedish Dementia Foundation (Demensförbundet), the Swedish Parkinson Foundation (Parkinsonfonden), Gamla Tjänarinnor Foundation, the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation, the Agneta Prytz-Folkes & Gösta Folkes Foundation (#2020-00124), the Gun and Bertil Stohnes Foundation, and the Anna Lisa and Brother Björnsson's Foundation. E.R.Z. receives financial support from CNPq (#435642/2018-9 and #312410/2018- 2), Instituto Serrapilheira (#Serra-1912-31365), Brazilian National Institute of Science and Technology in Excitotoxicity and Neuroprotection (#465671/2014-4), FAPERGS/MS/CNPq/SESRS-PPSUS (#30786.434.24734.231120170), and ARD/FAPERGS (#54392.632.30451.05032021).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Douglas Mental Health University Institute Research Ethics Board and the Montreal Neurological Instituted PET working committee approved this study. All participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data from the Translational Biomarkers in Aging and Dementia (TRIAD) study will be made available from the senior authors upon reasonable request. Such arrangements are subject to standard data-sharing agreements. Of note, the data used in the present work is not publicly available because the information could compromise the participants' privacy.
